Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib

被引：51
|
作者：
Kang, Jin [1 ,2 ,3 ]
Chen, Hua-Jun [2 ,3 ]
Wang, Zheng [4 ]
Liu, Jing [5 ]
Li, Bing [5 ]
Zhang, Tengfei [5 ]
Yang, Zhenfan [4 ]
Wu, Yi-Long [2 ,3 ,6 ]
Yang, Jin-Ji [1 ,2 ,3 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Cardiovasc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[3] Guangdong Gen Hosp, Guangdong Lung Canc Inst, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[4] AstraZeneca, Asia Innovat Med, Shanghai, Peoples R China
[5] Burning Rock Biotech, Guangzhou, Guangdong, Peoples R China
[6] Guangdong Gen Hosp, Med Res Ctr, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 04期
关键词：
ACQUIRED-RESISTANCE; CANCER;
D O I：
10.1016/j.jtho.2017.10.028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E49 / E53
页数：5
相关论文
共 50 条
  • [31] Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib
    Wu, Jia-Jun
    Tseng, Jeng-Sen
    Zheng, Zhe-Rong
    Chu, Cheng-Hsiang
    Chen, Kun-Chieh
    Lin, Mong-Wei
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Yang, Tsung-Ying
    Yu, Sung-Liang
    Chen, Jin-Shing
    Ho, Chao-Chi
    Chang, Gee-Chen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [32] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wenxian Wang
    Hong Wang
    Peihua Lu
    Zongyang Yu
    Chunwei Xu
    Wu Zhuang
    Zhengbo Song
    Journal of Translational Medicine, 17
  • [33] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wang, Wenxian
    Wang, Hong
    Lu, Peihua
    Yu, Zongyang
    Xu, Chunwei
    Zhuang, Wu
    Song, Zhengbo
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
  • [34] Local Ablative Therapy for Oligoprogressive, EGFR-Mutant, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib
    Kim, C.
    Roper, N.
    Hoang, C.
    Connolly, M.
    Cultraro, C.
    Szabo, E.
    Waris, M.
    Padiernos, E.
    Kesarwala, A.
    Gao, S.
    Steinberg, S.
    Wong, D.
    Khan, J.
    Rajan, A.
    Guha, U.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2146 - S2146
  • [35] Local ablative therapy for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib
    Kim, Chul
    Roper, Nitin
    Chuong Hoang
    Wisch, Laura
    Connolly, Maureen
    Chou, Hsien-Chao
    Wei, Jun
    Tyagi, Manoj
    Cultraro, Constance M.
    Xi, Liqiang
    Waris, Maryam
    Khoa Dang Nguyen
    Szabo, Eva
    Padiernos, Emerson
    Kesarwala, Aparna
    Gao, Shaojian
    Steinberg, Seth M.
    Raffeld, Mark
    Rajan, Arun
    Khan, Javed
    Guha, Udayan
    CANCER RESEARCH, 2018, 78 (13)
  • [36] Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance A case report
    Jiang, Yiqian
    Shou, Leyi
    Guo, Qingmin
    Bao, Yanhong
    Xu, Xiaoping
    An, Suhong
    Lu, Jianfeng
    MEDICINE, 2021, 100 (32) : E26911
  • [37] Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
    Lee, Po-Hsin
    Huang, Yen-Hsiang
    Lin, Ho
    Hsu, Kuo-Hsuan
    Chen, Kun-Chieh
    Tseng, Jeng-Sen
    Chang, Gee-Chen
    Yang, Tsung-Ying
    MEDICINA-LITHUANIA, 2022, 58 (07):
  • [38] Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization
    Bolan, Patrick O.
    Zviran, Asaf
    Brenan, Lisa
    Schiffman, Joshua S.
    Dusaj, Neville
    Goodale, Amy
    Piccioni, Federica
    Johannessen, Cory M.
    Landau, Dan A.
    CELL SYSTEMS, 2020, 10 (01) : 52 - +
  • [39] Impact of next-generation sequencing on clinical outcomes in advanced EGFR-mutant lung cancer patients after resistance to osimertinib.
    Cheng, Jia-Tao
    Yang, Jin-Ji
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer
    Nishima, Shunichi
    Miyanaga, Akihiko
    Saito, Sho
    Yuasa, Mizuki
    Takahashi, Satoshi
    Kashiwada, Takeru
    Sugano, Teppei
    Noro, Rintaro
    Minegishi, Yuji
    Terasaki, Yasuhiro
    Saito, Yoshinobu
    Kubota, Kaoru
    Seike, Masahiro
    Gemma, Akihiko
    INTERNAL MEDICINE, 2021, 60 (04) : 591 - 594
12345